Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.1053

Blood Malignancies in Mazandaran Province of Iran  

Tahmasby, Bahram (School of Health Management and Information Sciences, Tehran University of Medical Sciences)
Marnani, Ahmad Barati (School of Health Management and Information Sciences, Tehran University of Medical Sciences)
Maleki, Mohammadreza (School of Health Management and Information Sciences, Tehran University of Medical Sciences)
Barouni, Mohsen (Research Center for Health Services Management, Kerman University of Medical Sciences)
Mousavi, Seyyed Hamid (Education Development Center, Hormozgan University of Medical Sciences)
Naseriyan, Behjat (Education Development Center, Hormozgan University of Medical Sciences)
Nazarnezhad, Mirzaali (Education Development Center, Hormozgan University of Medical Sciences)
Alizadeh, Ali (Research Center for Social Determinant in Health Promotion, Department of Research and Teechnology, Hormozgan University of Medical Sciences)
Sabermahani, Asma (Research Center for modeling in health, Institute of Futures Studies in Health, Kerman University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 1053-1056 More about this Journal
Abstract
Background: Leukemia and lymphoma demonstrate significantly incidence rates throughout the world and particularly in Iran they cause serious mortality and diagnosis and treatment expenditures for both families and the health system. Combined they account for about 11 percent of cancers in Mazandaran province, ranking number 2 in prevalent cancers. The purpose of this study was to provide a first general and specific description of leukemia and lymphoma in Mazandaran province. Materials and Methods: In this descriptive retrospective study, entire patient's data were reviewed which had confirmed diagnosis of leukemia and lymphoma with valid laboratory or pathology reports in the period 2001-2008. The data were collected by Babol health research site related to Tehran University of Medical Science. Incidence rates based on age groups, gender, city of residence and type of malignancy were calculated and analyzed. Results: In Mazandaran province, 1,146 cases of leukemia and lymphoma were encountered, 5.9 in 100,000 persons on average annually. The highest incidence rates were obtained at age of 70 or above (26.4) and the lowest at age of 0-9 (2.3).The incidence rates in males and females were 7.1 and 4.8 respectively with a ratio of 1.5. The highest incidence rate was in Babol (7.3) and the lowest was calculated in Neka and Tonekabon equally (1.5). According to the type of malignancy, non Hodgkin lymphoma, with 2.5/100,000 have the most incidence rate and myeloid leukemia with 1.8 had the lowest. Conclusions: The obtained findings indicate clear differences in incidence rates based on age, gender, residence, and type of malignancy. Therefore it's suggested that in addition to promote data collecting programs, research projects should be programmed to define leukemia and lymphoma risk factors in this province.
Keywords
Leukemia; lymphoma; blood malignancy; incidence; Mazandaran province; Iran;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ansel SM, Armitage JO (2006). Management of hodgkin lymphoma. Mayo Clin Proc, 81, 419.   DOI   ScienceOn
2 Arlene DN, Janet EM,Victor GV (). Epidemiology of cancer and prevention strategies; 1995, MD Anderson Cancer Center, Houston, texas.
3 Baccarani M, Cortes J, Pane F, Niederwieser D, et al (2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemia Net. J Clin Oncol, 27, 6041.   DOI   ScienceOn
4 Dohner H, Estey EH, Amadori S, et al (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood, 115, 453-74.   DOI   ScienceOn
5 Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008 v2.0: cancer incidence and mortality worldwide: IARC Cancer Base No. 10, 2010.
6 Goldman L, Andrew IS (2012). Goldman's Cecil Medicine: 24thEdition; 2012 (Section15; Page: 1203-1233).
7 Jemal A, Siegel R, Ward E, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.   DOI
8 Longo D, Anthony F, Dennis K, et al (2011). Harrison's principles of internal medicine: 18th Edition, 2011 (Part7; Page: 435-470).
9 Longo Dan, Tinsley Randolph Harrison: Harrison's Hematology and Oncology; First edition, 2010; section 5.
10 Mahmoudy M, Yahyapour Y, Alijantabar J (1995). Annual reports of 1992-1995; Babol health research center belongs to Tehran University of Medical Science (In Persian), 1995.
11 Peter HW, John MG, Janice PD, Robert AK (2013). Neoplastic Diseases of the Blood; 5th Edition, 2013.
12 Punnett A, Tsang RW, Hodgson DC (2010). Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol, 20, 30-44.   DOI   ScienceOn
13 Robert MK, Bonita MD S, Joseph St G, et al (2011). Nelson Textbook of Pediatrics: 19th Edition: 2011 (Part 22; Chapter: 489-490).
14 Sandler DP, Ross JA (1997). Epidemiology of acute leukemia in children and adults: Seminars. Oncology, 24, 3-16.
15 Sant M, Claudia A, Carmen T, et al (2010). Incidence of hematologic malignancies in Europe by morphologic subtype. J America society of hematology; 2010.
16 Wiesenberger DD (1994). Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol, 5, 19-24.   DOI